Hardware is rarely the bottleneck. The equipment arrives. What arrives late is the integration between the people who design the facility, the people who will hold the licence, and the people who will run production to a schedule. Success depends on a single team working to one baseline model from feasibility through to operations.
Validation is not a phase at the end. Validation scope drives cleanroom design, staffing, documentation and timeline from the very first drawing. Retrofitting it after construction is the single most expensive correction in these projects, and one of the most common.
Utilisation economics decide the P&L. Uptime, beam-time scheduling, QC turnaround and last-mile logistics all run against a half-life clock. A dose that misses its slot is not delayed revenue — it is gone. Preventive maintenance, critical spares, calibrated instruments and strict SOPs are financial controls, not housekeeping.
Theranostics readiness has to be designed in. PET supply, pharmacy throughput, QC capacity, radiation protection and discharge rules all shape cost and utilisation. Added later, they become bottlenecks that cap the very therapy volumes the investment was justified on.
Cyclotrons behave like infrastructure. Large upfront capex, steady but moderate cashflow, long payback. They reward strategic commitment and punish opportunistic bets — which is why the funding structure and the operating plan have to be built together.